Furthermore, the randomized, phase III trial, ATTRACTION-3 (NCT02569242, ONO-4538-24/CA209-473) is performing to compare nivolumab with chemotherapy (docetaxel or paclitaxel) as second-line therapy in unresectable or recurrent ESCC patients with PD-L1-unselected (44). Here, CD274 is linked to esophageal squamous cell carcinoma.